Nanobiotix S.A.

NasdaqGS:NBTX Stock Report

Market Cap: US$1.9b

Nanobiotix Future Growth

Future criteria checks 5/6

Nanobiotix is forecast to grow earnings and revenue by 55.6% and 20.9% per annum respectively while EPS is expected to grow by 55.7% per annum.

Key information

55.6%

Earnings growth rate

55.68%

EPS growth rate

Biotechs earnings growth25.1%
Revenue growth rate20.9%
Future return on equityn/a
Analyst coverage

Good

Last updated03 Jun 2026

Recent future growth updates

No updates

Recent updates

Seeking Alpha • Jun 25

Nanobiotix: A Highly Speculative Bet On A Potential Radiotherapy Platform

Summary Nanobiotix is rated a strong speculative Buy, driven by risk-adjusted upside from its JNJ-1900 radioenhancer platform in partnership with Janssen. NBTX’s lead indication, head and neck cancer, offers a modeled $624M valuation, but lung cancer programs—despite higher risk—represent two-thirds of the $4.5B risk-adjusted opportunity. JNJ-1900’s platform potential is vast, with even low-probability broad adoption scenarios materially boosting valuation; upcoming clinical milestones in 2026–2027 are pivotal. Current cash runway extends into 2029, reducing near-term financing risk, while the Johnson & Johnson partnership de-risks late-stage development and supports multi-indication expansion. Current development programs target only a fraction of the potential injectable radiotherapy market, leaving substantial long-term platform optionality. Read the full article on Seeking Alpha
Seeking Alpha • Oct 18

Nanobiotix enters final agreement to restructure existing loan with EU's investment bank

French biotech Nanobiotix (NASDAQ:NBTX) on Tuesday said it had reached a final agreement with the European Investment Bank (EIB) to re-align about €30.7M in outstanding debt obligations with its expected development and commercialization timelines. The company had previously announced the agreement-in-principle with the EIB in mid-Sept. As per the newly executed final agreement, NBTX can now defer repayment of the remaining €25.3M of the loan set to be paid in two tranches up to June 2029. The restructuring agreement also includes a new milestone payment of €20M due in June 2029. U.S.-listed shares of NBTX -2.4% to $4 after hours.
Seeking Alpha • Sep 28

Nanobiotix GAAP EPS of -€0.76, revenue of €1.33M beats by €0.11M

Nanobiotix press release (NASDAQ:NBTX): 1H GAAP EPS of -€0.76. Revenue of €1.33M (+0.8% Y/Y) beats by €0.11M. Cash and Cash Equivalents: Cash and cash equivalents as of June 30, 2022, were €63.0 million, compared to €83.9 million as of December 31, 2021.
Seeking Alpha • Sep 12

Nanobiotix agrees in principle to restructure debt obligations with EU's investment bank

French biotech Nanobiotix (NASDAQ:NBTX) on Monday said it had reached an agreement in principle to restructure €30.7M in outstanding debt obligations related to its 2018 loan agreement with the European Investment Bank. NBTX said the debt restructuring was done to realign debt obligations with the company's development and commercialization timelines. The company said that execution of the amendment to the debt obligations is expected in Q4 2022 after the legal documents are finalized. "Restructuring existing debt obligations to extend the maturity date of the loan will enable Nanobiotix to drive priority development programs in 2023 by extending operating runway an additional quarter," NBTX CFO Bart Van Rhijn said in a statement. NBTX said the restructuring of the debt obligations combined with capital available through its existing equity line allows the company to extend its operating runway into Q1 2024. U.S.-listed shares of NBTX +0.2% to $4.17 in mid-day trading.
Seeking Alpha • Aug 01

French biotech Nanobiotix rebounds to post best ever 47% intraday gain

ADRs of Paris-based clinical-stage biotech Nanobiotix S.A. (NASDAQ:NBTX) recovered from a sharp selloff on Monday to record the biggest ever intraday gain thanks to strong trading volumes. Nanobiotix (NBTX) plunged nearly 30% on above-average volume to reach an all-time low on Friday. However, the stock has added ~47% on Monday, with nearly 34.4K ADRs changing hands compared to the 65-day average of ~1.1K. This quarter, Nanobiotix (NBTX) is on track to launch its first U.S. clinical trial sites in an ongoing pivotal Phase 3 trial for lead candidate NBTXR3 in head and neck squamous cell carcinoma. Its partner for the program, LianBio (LIAN) also plans to activate the first trial site and dose the first patient in Asia in H2 2022 for the candidate against the same indication.

Earnings and Revenue Growth Forecasts

NasdaqGS:NBTX - Analysts future estimates and past financials data (EUR Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/2028882977566
12/31/20275538-127
12/31/202644-10-30-237
12/31/202533-24-34-33N/A
9/30/202521-38-33-32N/A
6/30/202510-52-32-31N/A
3/31/20251-60-26-25N/A
12/31/2024-7-68-20-20N/A
9/30/202418-51-11-10N/A
6/30/202442-33-2-1N/A
3/31/202439-37-7-7N/A
12/31/202336-40-13-12N/A
9/30/202321-49-25-25N/A
6/30/20237-59-37-37N/A
3/31/20236-58-37-37N/A
12/31/20225-57-37-37N/A
9/30/20224-50-35-35N/A
6/30/20223-43-33-32N/A
3/31/20223-45-31-31N/A
12/31/20213-47-30-30N/A
9/30/20212-45-30-30N/A
6/30/20212-43-30-30N/A
3/31/20212-39-29-29N/A
12/31/20202-34-28-28N/A
9/30/20202-41-31-30N/A
6/30/20202-48-33-33N/A
3/31/20202-49-38-37N/A
12/31/20193-51-43-41N/A
9/30/20193-46N/A-37N/A
6/30/20193-42N/A-33N/A
3/31/20193-36N/A-30N/A
12/31/20183-30N/A-26N/A
9/30/20184-28N/A-24N/A
6/30/20184-27N/A-22N/A
3/31/20184-26N/A-22N/A
12/31/20174-26N/A-21N/A
9/30/20174-25N/A-20N/A
6/30/20174-24N/A-19N/A
3/31/20175-23N/A-19N/A
12/31/20165-22N/A-18N/A
9/30/20165-21N/A-19N/A
6/30/20165-19N/A-20N/A
3/31/20165-18N/A-19N/A
12/31/20154-17N/A-17N/A
9/30/20154-15N/A-15N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: NBTX is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (3.5%).

Earnings vs Market: NBTX is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: NBTX is expected to become profitable in the next 3 years.

Revenue vs Market: NBTX's revenue (20.9% per year) is forecast to grow faster than the US market (12.7% per year).

High Growth Revenue: NBTX's revenue (20.9% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if NBTX's Return on Equity is forecast to be high in 3 years time

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/07/07 22:01
End of Day Share Price 2026/07/07 00:00
Earnings2025/12/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Nanobiotix S.A. is covered by 18 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Philippa GardnerEdison Investment Research
Jonathan MillerEvercore ISI
Emmanuel ParotGilbert Dupont